Because of the “rebound hyperglycemia”, the change-in-MGC curves (Fig. 1, b) began to flatten when the IR was severe and the dose of SQ increased above 4 U. This picture signaled a nonlinear dose-response relation between SQ Lispro insulin and MGC in patients with severe IR: a potential important observation for the design of sliding-scale SQ Lispro insulin protocols for such patients. The gene discussed is INS; the disease is Hyperglycemia.